Connect
← Return to Nanoknife for pancreatic cancer
Discussion
Nanoknife for pancreatic cancer
Pancreatic Cancer | Last Active: Nov 17, 2024 | Replies (47)Comment receiving replies
I continue on the Revolution Medicine trial for KRAS mutations. I am on the combo drugs 9805/6236. I am in a thread with people on 6236. So far I have heard of stable tumors /no progression/shrinkage. I have seen shrinkage and CA-9-9 declining significantly.
A drug to keep an eye on if you have KRAS mutations. Also MiratA has one but not connected to those results.
Cisplatin is the root cause of neuropathy when given with the chemo drugs we all take.
Replies to "I continue on the Revolution Medicine trial for KRAS mutations. I am on the combo drugs..."
Cis-platin, oxaliplatin which is the platin agent used in (m)Folfirinox and taxanes such as Abraxane (nab-Paclitaxel) are all neurotoxic and can cause chemo induced peripheral neuropathy. More pancreatic oncologists are beginning to consider using cold therapy to improve quality of life and patient experience for patients on these neurotoxic agents
Connect
I’m happy to hear that - we are hopeful to start the KRAS trial with the pills next at Stage 3 trial. We would like to try that before the Fulforinox, not wanting to exhaust both proven standards of care.